“…A total 89 of patients with CSU were enrolled in seven studies (n = 2-28) and a significant improvement in DLQI scores was obtained following omalizumab treatment (Kai, Flohr, & Grattan, 2014;Kaplan, Joseph, Maykut, Geba, & Zeldin, 2008;Lefévre, Deleuran, & Vestergaard, 2013;Marcelino et al, 2018;Savic et al, 2015;Subramaniyan & Chopra, 2016;Vestergaard & Deleuran, 2010). Accordingly with our results, the decrease in DLQI scores was most significant during the first month of treatment and then stabilized as long as the treatment is continued (Kai et al, 2014;Lefévre et al, 2013;Vestergaard & Deleuran, 2010 Consistently with our findings, two previous studies including 14 and 18 patients have reported a significant decrease in CU-Q2oL-total scores which was maintained up to 6 months (Büyüköztürk et al, 2012;Larrea-Baca & Gurpegui-Resano, 2017). Accordingly with the present study, in a recent prospective study of 117 patients, a DLQItotal score of 0/1, that indicates no effect on patients' life, has been obtained in 35.8% of the patients at third month (Ghazanfar, Holm, & Thomsen, 2018).…”